The New York Stem Cell Foundation Research Institute, New York, NY, 10032, USA,
Stem Cell Rev Rep. 2015 Aug;11(4):652-65. doi: 10.1007/s12015-015-9586-8.
Human peripheral blood and umbilical cord blood represent attractive sources of cells for reprogramming to induced pluripotent stem cells (iPSCs). However, to date, most of the blood-derived iPSCs were generated using either integrating methods or starting from T-lymphocytes that have genomic rearrangements thus bearing uncertain consequences when using iPSC-derived lineages for disease modeling and cell therapies. Recently, both peripheral blood and cord blood cells have been reprogrammed into transgene-free iPSC using the Sendai viral vector. Here we demonstrate that peripheral blood can be utilized for medium-throughput iPSC production without the need to maintain cell culture prior to reprogramming induction. Cell reprogramming can also be accomplished with as little as 3000 previously cryopreserved cord blood cells under feeder-free and chemically defined Xeno-free conditions that are compliant with standard Good Manufacturing Practice (GMP) regulations. The first iPSC colonies appear 2-3 weeks faster in comparison to previous reports. Notably, these peripheral blood- and cord blood-derived iPSCs are free of detectable immunoglobulin heavy chain (IGH) and T cell receptor (TCR) gene rearrangements, suggesting they did not originate from B- or T- lymphoid cells. The iPSCs are pluripotent as evaluated by the scorecard assay and in vitro multi lineage functional cell differentiation. Our data show that small volumes of cryopreserved peripheral blood or cord blood cells can be reprogrammed efficiently at a convenient, cost effective and scalable way. In summary, our method expands the reprogramming potential of limited or archived samples either stored at blood banks or obtained from pediatric populations that cannot easily provide large quantities of peripheral blood or a skin biopsy.
人外周血和脐带血是重编程为诱导多能干细胞(iPSC)的有吸引力的细胞来源。然而,迄今为止,大多数血液来源的 iPSC 是使用整合方法或从带有基因组重排的 T 淋巴细胞产生的,因此在使用 iPSC 衍生谱系进行疾病建模和细胞治疗时存在不确定的后果。最近,使用仙台病毒载体将外周血和脐带血细胞重编程为无转基因 iPSC。在这里,我们证明可以在外周血中进行高通量 iPSC 生产,而无需在重编程诱导之前维持细胞培养。在无饲养细胞和无化学定义的 Xeno-free 条件下,仅使用 3000 个先前冷冻保存的脐带血细胞即可完成细胞重编程,这些条件符合标准良好生产规范(GMP)法规。与之前的报告相比,第一株 iPSC 集落出现的速度快了 2-3 周。值得注意的是,这些外周血和脐带血来源的 iPSC 中没有可检测到的免疫球蛋白重链(IGH)和 T 细胞受体(TCR)基因重排,表明它们不是来自 B 或 T 淋巴细胞。通过计分板测定和体外多谱系功能细胞分化评估,这些 iPSC 具有多能性。我们的数据表明,可以以方便、经济高效且可扩展的方式有效地重编程小体积的冷冻保存外周血或脐带血细胞。总之,我们的方法扩展了有限或存档样本的重编程潜力,这些样本存储在血液库中或从儿科人群中获得,这些人群难以提供大量外周血或皮肤活检。